Skip to main content
Erschienen in: Current Allergy and Asthma Reports 2/2014

01.02.2014 | RHINOSINUSITIS (J MULLOL, SECTION EDITOR)

The Common Cold: Potential for Future Prevention or Cure

verfasst von: Maria Passioti, Paraskevi Maggina, Spyridon Megremis, Nikolaos G. Papadopoulos

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The common cold is the most frequent, although generally mild, human disease. Human Rhinoviruses are the prevalent causative agents, but other viruses are also implicated. Being so common, viral colds, have significant implications on public health and quality of life, but may also be life-threatening for vulnerable groups of patients. Specific diagnosis and treatment of the common cold still remain unmet needs. Molecular diagnostic techniques allow specific detection of known pathogens as well as the identification of newly emerging viruses. Although a number of medications or natural treatments have been shown to have some effect, either on the number or on the severity of common colds, no single agent is considerably effective. Virus-specific management remains in most cases a challenging potential as many factors have to be taken into account, including the diversity of the viral genomes, the heterogeneity of affected individuals, as well as the complexity of this long standing host-virus relationship.
Literatur
1.
Zurück zum Zitat Fokkens WJ et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:3. p preceding table of contents, 1–298.PubMed Fokkens WJ et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:3. p preceding table of contents, 1–298.PubMed
2.
Zurück zum Zitat Heikkinen T, Jarvinen A. The common cold. Lancet. 2003;361(9351):51–9.PubMed Heikkinen T, Jarvinen A. The common cold. Lancet. 2003;361(9351):51–9.PubMed
3.
Zurück zum Zitat Roelen CA, Koopmans PC, Notenbomer A, Groothoff JW, et al. Job satisfaction and short sickness absence due to the common cold. Work. 2011;39(3):305–13.PubMed Roelen CA, Koopmans PC, Notenbomer A, Groothoff JW, et al. Job satisfaction and short sickness absence due to the common cold. Work. 2011;39(3):305–13.PubMed
4.
Zurück zum Zitat Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2013;6, CD000247.PubMed Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2013;6, CD000247.PubMed
5.
Zurück zum Zitat Leder K, Sinclair MI, Mitakakis TZ, Hellard ME, Forbes A. A community-based study of respiratory episodes in Melbourne, Australia. Aust N Z J Public Health. 2003;27(4):399–404.PubMed Leder K, Sinclair MI, Mitakakis TZ, Hellard ME, Forbes A. A community-based study of respiratory episodes in Melbourne, Australia. Aust N Z J Public Health. 2003;27(4):399–404.PubMed
6.
Zurück zum Zitat Gruber C et al. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol. 2008;19(6):505–12.PubMed Gruber C et al. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol. 2008;19(6):505–12.PubMed
7.
Zurück zum Zitat Ball TM et al. Influence of attendance at day care on the common cold from birth through 13 years of age. Arch Pediatr Adolesc Med. 2002;156(2):121–6.PubMed Ball TM et al. Influence of attendance at day care on the common cold from birth through 13 years of age. Arch Pediatr Adolesc Med. 2002;156(2):121–6.PubMed
8.
Zurück zum Zitat Pitkaranta A et al. Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J Clin Virol. 1999;14(3):199–205.PubMed Pitkaranta A et al. Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J Clin Virol. 1999;14(3):199–205.PubMed
9.
Zurück zum Zitat Cohen S et al. Positive emotional style predicts resistance to illness after experimental exposure to rhinovirus or influenza a virus. Psychosom Med. 2006;68(6):809–15.PubMed Cohen S et al. Positive emotional style predicts resistance to illness after experimental exposure to rhinovirus or influenza a virus. Psychosom Med. 2006;68(6):809–15.PubMed
10.
Zurück zum Zitat Herlov-Nielsen H, Permin H. Common cold–risk factors, transmission and treatment. Ugeskr Laeger. 2001;163(41):5643–6.PubMed Herlov-Nielsen H, Permin H. Common cold–risk factors, transmission and treatment. Ugeskr Laeger. 2001;163(41):5643–6.PubMed
11.
Zurück zum Zitat Nieman DC. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc. 1994;26(2):128–39.PubMed Nieman DC. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc. 1994;26(2):128–39.PubMed
12.
Zurück zum Zitat Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539–42.PubMedCentralPubMed Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539–42.PubMedCentralPubMed
13.
Zurück zum Zitat Monto AS. Epidemiology of viral respiratory infections. Am J Med. 2002;112(Suppl 6A):4S–12S.PubMed Monto AS. Epidemiology of viral respiratory infections. Am J Med. 2002;112(Suppl 6A):4S–12S.PubMed
14.
Zurück zum Zitat Grief SN. Upper respiratory infections. Prim Care. 2013;40(3):757–70.PubMed Grief SN. Upper respiratory infections. Prim Care. 2013;40(3):757–70.PubMed
15.
Zurück zum Zitat Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med. 2012;18(3):271–8.PubMed Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med. 2012;18(3):271–8.PubMed
16.
Zurück zum Zitat Weigl JA et al. Ten years' experience with year-round active surveillance of up to 19 respiratory pathogens in children. Eur J Pediatr. 2007;166(9):957–66.PubMed Weigl JA et al. Ten years' experience with year-round active surveillance of up to 19 respiratory pathogens in children. Eur J Pediatr. 2007;166(9):957–66.PubMed
17.
Zurück zum Zitat Kahn J. Human bocavirus: clinical significance and implications. Curr Opin Pediatr. 2008;20(1):62–6.PubMed Kahn J. Human bocavirus: clinical significance and implications. Curr Opin Pediatr. 2008;20(1):62–6.PubMed
18.
Zurück zum Zitat Gwaltney Jr JM et al. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275(23):1261–8.PubMed Gwaltney Jr JM et al. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275(23):1261–8.PubMed
19.
Zurück zum Zitat Monto AS, Johnson KM. A community study of respiratory infections in the tropics. II. The spread of six rhinovirus isolates within the community. Am J Epidemiol. 1968;88(1):55–68.PubMed Monto AS, Johnson KM. A community study of respiratory infections in the tropics. II. The spread of six rhinovirus isolates within the community. Am J Epidemiol. 1968;88(1):55–68.PubMed
20.
Zurück zum Zitat Briese T et al. Global distribution of novel rhinovirus genotype. Emerg Infect Dis. 2008;14(6):944–7.PubMed Briese T et al. Global distribution of novel rhinovirus genotype. Emerg Infect Dis. 2008;14(6):944–7.PubMed
21.
Zurück zum Zitat Arakawa M, Okamoto-Nakagawa R, Toda S, Tsukagoshi H, Kobayashi M, Ryo A. Molecular epidemiological study of human rhinovirus species A, B and C from patients with acute respiratory illnesses in Japan. J Med Microbiol. 2012;61(3):410–9.PubMed Arakawa M, Okamoto-Nakagawa R, Toda S, Tsukagoshi H, Kobayashi M, Ryo A. Molecular epidemiological study of human rhinovirus species A, B and C from patients with acute respiratory illnesses in Japan. J Med Microbiol. 2012;61(3):410–9.PubMed
22.
Zurück zum Zitat Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011;7, CD006207.PubMed Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011;7, CD006207.PubMed
23.
Zurück zum Zitat Gern JE et al. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med. 2000;162(6):2226–31.PubMed Gern JE et al. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med. 2000;162(6):2226–31.PubMed
24.•
Zurück zum Zitat Jacobs SE et al. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–62. This review provides a summary of pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for RVs. PubMedCentralPubMed Jacobs SE et al. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–62. This review provides a summary of pathogenesis, clinical epidemiology, and laboratory features of and treatment and prevention strategies for RVs. PubMedCentralPubMed
25.
Zurück zum Zitat Winther B et al. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol. 1984;97(3–4):309–18.PubMed Winther B et al. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol. 1984;97(3–4):309–18.PubMed
26.•
Zurück zum Zitat Triantafilou K, Vakakis E, Richer EA, Evans GL, Villiers JP, Triantafilou M. Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response. Virulence. 2011;2(1):22–9. This article gives insight on the host's immune response mechanisms during common cold caused by rhinovirus that give rise to inflammation that defines common cold symptoms. PubMed Triantafilou K, Vakakis E, Richer EA, Evans GL, Villiers JP, Triantafilou M. Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response. Virulence. 2011;2(1):22–9. This article gives insight on the host's immune response mechanisms during common cold caused by rhinovirus that give rise to inflammation that defines common cold symptoms. PubMed
27.
Zurück zum Zitat Papadopoulos NG et al. Rhinoviruses infect the lower airways. J Infect Dis. 2000;181(6):1875–84.PubMed Papadopoulos NG et al. Rhinoviruses infect the lower airways. J Infect Dis. 2000;181(6):1875–84.PubMed
28.
Zurück zum Zitat Lessler J et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291–300.PubMed Lessler J et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291–300.PubMed
29.
Zurück zum Zitat Harris 2nd JM, Gwaltney Jr JM. Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis. 1996;23(6):1287–90.PubMed Harris 2nd JM, Gwaltney Jr JM. Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis. 1996;23(6):1287–90.PubMed
30.
Zurück zum Zitat Gwaltney Jr JM, Hendley JO, Patrie JT. Symptom severity patterns in experimental common colds and their usefulness in timing onset of illness in natural colds. Clin Infect Dis. 2003;36(6):714–23.PubMed Gwaltney Jr JM, Hendley JO, Patrie JT. Symptom severity patterns in experimental common colds and their usefulness in timing onset of illness in natural colds. Clin Infect Dis. 2003;36(6):714–23.PubMed
31.
Zurück zum Zitat Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis. 2011;204(11):1702–10.PubMed Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis. 2011;204(11):1702–10.PubMed
32.
Zurück zum Zitat Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB. Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282–90.PubMed Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB. Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282–90.PubMed
33.
Zurück zum Zitat Graat JM, Schouten EG, Heijnen ML, Kok FJ, Pallast EG, de Greeff SC, et al. A prospective, community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection. J Clin Epidemiol. 2003;56(12):1218–23.PubMed Graat JM, Schouten EG, Heijnen ML, Kok FJ, Pallast EG, de Greeff SC, et al. A prospective, community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection. J Clin Epidemiol. 2003;56(12):1218–23.PubMed
34.
Zurück zum Zitat Armengol CE, Hendley JO, Winther B. Occurrence of acute otitis media during colds in children younger than four years. Pediatr Infect Dis J. 2011;30(6):518–20.PubMed Armengol CE, Hendley JO, Winther B. Occurrence of acute otitis media during colds in children younger than four years. Pediatr Infect Dis J. 2011;30(6):518–20.PubMed
35.
Zurück zum Zitat Marom T, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions in acute otitis media. Curr Allergy Asthma Rep. 2000;12(6):551–8. Marom T, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions in acute otitis media. Curr Allergy Asthma Rep. 2000;12(6):551–8.
36.
Zurück zum Zitat Esposito S, Marchisio P, Tenconi R, Tagliaferri L, Albertario G, Patria MF, et al. Diagnosis of acute rhinosinusitis. Pediatr Allergy Immunol. 2012;23(22):17–9.PubMed Esposito S, Marchisio P, Tenconi R, Tagliaferri L, Albertario G, Patria MF, et al. Diagnosis of acute rhinosinusitis. Pediatr Allergy Immunol. 2012;23(22):17–9.PubMed
37.
Zurück zum Zitat Welge-Lussen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Adv Otorhinolaryngol. 2006;63:125–32.PubMed Welge-Lussen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Adv Otorhinolaryngol. 2006;63:125–32.PubMed
38.
Zurück zum Zitat Papadopoulos NG. Do rhinoviruses cause pneumonia in children? Paediatr Respir Rev. 2004;5(A):S191–5.PubMed Papadopoulos NG. Do rhinoviruses cause pneumonia in children? Paediatr Respir Rev. 2004;5(A):S191–5.PubMed
39.
Zurück zum Zitat Ruuskanen O et al. Viral pneumonia. Lancet. 2011;377(9773):1264–75.PubMed Ruuskanen O et al. Viral pneumonia. Lancet. 2011;377(9773):1264–75.PubMed
40.
Zurück zum Zitat Corne JM et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–4.PubMed Corne JM et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–4.PubMed
41.
Zurück zum Zitat Papadopoulos NG et al. Viruses and bacteria in acute asthma exacerbations–a GA(2) LEN-DARE systematic review. Allergy. 2011;66(4):458–68.PubMed Papadopoulos NG et al. Viruses and bacteria in acute asthma exacerbations–a GA(2) LEN-DARE systematic review. Allergy. 2011;66(4):458–68.PubMed
42.
Zurück zum Zitat Wark PA et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47.PubMedCentralPubMed Wark PA et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47.PubMedCentralPubMed
43.
Zurück zum Zitat Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4):896–904.PubMed Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4):896–904.PubMed
44.
Zurück zum Zitat de Almeida MB, Zerbinati RM, Tateno AF, Oliveira CM, Romão RM, Rodrigues JC, et al. Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg Infect Dis. 2010;16(6):996–9.PubMed de Almeida MB, Zerbinati RM, Tateno AF, Oliveira CM, Romão RM, Rodrigues JC, et al. Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg Infect Dis. 2010;16(6):996–9.PubMed
45.
Zurück zum Zitat Crooks BN, Taylor CE, Turner AJ, Osman HK, Abinun M, Flood TJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097–102.PubMed Crooks BN, Taylor CE, Turner AJ, Osman HK, Abinun M, Flood TJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097–102.PubMed
46.•
Zurück zum Zitat Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Marshall Lyon G. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50(3):1061–3. This study demonstrates that human rhinovirus infection is associated with significant morbidity and mortality in immunocompromised individuals. PubMedCentralPubMed Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Marshall Lyon G. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50(3):1061–3. This study demonstrates that human rhinovirus infection is associated with significant morbidity and mortality in immunocompromised individuals. PubMedCentralPubMed
47.
Zurück zum Zitat Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S, et al. Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses. J Clin Microbiol. 2011;49(6):2138–42.PubMedCentralPubMed Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S, et al. Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses. J Clin Microbiol. 2011;49(6):2138–42.PubMedCentralPubMed
48.
Zurück zum Zitat Landry ML, Cohen S, Ferguson D. Impact of sample type on rapid detection of influenza virus A by cytospin-enhanced immunofluorescence and membrane enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38(1):429–30.PubMedCentralPubMed Landry ML, Cohen S, Ferguson D. Impact of sample type on rapid detection of influenza virus A by cytospin-enhanced immunofluorescence and membrane enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38(1):429–30.PubMedCentralPubMed
49.
Zurück zum Zitat Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-Venermo M. Human bocavirus-the first 5 years. Rev Med Virol. 2012;22(1):46–64.PubMed Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-Venermo M. Human bocavirus-the first 5 years. Rev Med Virol. 2012;22(1):46–64.PubMed
50.
Zurück zum Zitat Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci. 2011;48(5–6):217–49.PubMed Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci. 2011;48(5–6):217–49.PubMed
51.
Zurück zum Zitat Jartti T, Söderlund-Venermo M, Hedman K, Ruuskanen O, Mäkelä MJ. New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev. 2013;14(1):38–45.PubMed Jartti T, Söderlund-Venermo M, Hedman K, Ruuskanen O, Mäkelä MJ. New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev. 2013;14(1):38–45.PubMed
52.
Zurück zum Zitat Turner RB, Fuls JL, Rodgers ND, Goldfarb HB, Lockhart LK, Aust LB. A randomized trial of the efficacy of hand disinfection for prevention of rhinovirus infection. Clin Infect Dis. 2012;54(10):1422–6.PubMed Turner RB, Fuls JL, Rodgers ND, Goldfarb HB, Lockhart LK, Aust LB. A randomized trial of the efficacy of hand disinfection for prevention of rhinovirus infection. Clin Infect Dis. 2012;54(10):1422–6.PubMed
53.•
Zurück zum Zitat Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7. A clinical study of a novel influenza vaccine designed to boost cross-reactive immune responses to all influenza A subtypes. PubMed Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7. A clinical study of a novel influenza vaccine designed to boost cross-reactive immune responses to all influenza A subtypes. PubMed
54.
Zurück zum Zitat Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine. 2013;31(48):5706–12.PubMed Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine. 2013;31(48):5706–12.PubMed
55.
Zurück zum Zitat Simancas-Racines D, Guerra CV, Hidalgo R. Vaccines for the common cold. Cochrane Database Syst Rev. 2013;6, CD002190.PubMed Simancas-Racines D, Guerra CV, Hidalgo R. Vaccines for the common cold. Cochrane Database Syst Rev. 2013;6, CD002190.PubMed
56.
Zurück zum Zitat Fu YH, He JS, Qiao W, Jiao YY, Hua Y, Zhang Y, et al. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J. 2013;10:183.PubMedCentralPubMed Fu YH, He JS, Qiao W, Jiao YY, Hua Y, Zhang Y, et al. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J. 2013;10:183.PubMedCentralPubMed
57.•
Zurück zum Zitat Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012;7(5):e36812. Study describing a safe and effective intramuscular virosomal RSV vaccine adjuvanted with Monophosphoryl Lipid A in mice. PubMedCentralPubMed Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012;7(5):e36812. Study describing a safe and effective intramuscular virosomal RSV vaccine adjuvanted with Monophosphoryl Lipid A in mice. PubMedCentralPubMed
58.•
Zurück zum Zitat Rigter A, Widjaja I, Versantvoort H, Coenjaerts FEJ, van Roosmalen M, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One. 2013;8(8):e71072. Study describing a safe and effective intranasal vaccine in mice and cotton rats that is based on recombinant fusion (F) protein bound to the surface of immunostimulatory bacterium. PubMedCentralPubMed Rigter A, Widjaja I, Versantvoort H, Coenjaerts FEJ, van Roosmalen M, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One. 2013;8(8):e71072. Study describing a safe and effective intranasal vaccine in mice and cotton rats that is based on recombinant fusion (F) protein bound to the surface of immunostimulatory bacterium. PubMedCentralPubMed
59.
Zurück zum Zitat Palmenberg AC et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science. 2009;324(5923):55–9.PubMed Palmenberg AC et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science. 2009;324(5923):55–9.PubMed
60.•
Zurück zum Zitat Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med. 2011;17(5):627–32. Study describing for the first time the propagation of two HRV-C isolates in organ culture of nasal epithelial cells, sequencing a new C15 isolate, developed the first reverse genetics system for HRV-C and predicted a unique cell attachment site for HRV-Cs. PubMedCentralPubMed Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med. 2011;17(5):627–32. Study describing for the first time the propagation of two HRV-C isolates in organ culture of nasal epithelial cells, sequencing a new C15 isolate, developed the first reverse genetics system for HRV-C and predicted a unique cell attachment site for HRV-Cs. PubMedCentralPubMed
61.•
Zurück zum Zitat Megremis S, Demetriou P, Makrinioti H, Manoussaki AE, Papadopoulos NG. The genomic signature of human rhinoviruses A, B and C. PLoS One. 2012;7(9):e44557. Study presents for the first time the genomic signature of 111 fully sequenced HRV strains from all three groups HRV-A, HRV-B and HRV-C and propose a mechanism for the rapid changes in the HRV genomic sequence under the immune-driven pressures. PubMedCentralPubMed Megremis S, Demetriou P, Makrinioti H, Manoussaki AE, Papadopoulos NG. The genomic signature of human rhinoviruses A, B and C. PLoS One. 2012;7(9):e44557. Study presents for the first time the genomic signature of 111 fully sequenced HRV strains from all three groups HRV-A, HRV-B and HRV-C and propose a mechanism for the rapid changes in the HRV genomic sequence under the immune-driven pressures. PubMedCentralPubMed
62.
Zurück zum Zitat Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204.PubMedCentralPubMed Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204.PubMedCentralPubMed
63.••
Zurück zum Zitat Niespodziana K, Napora K, Cabauatan C, Focke-Tejkl M, Keller W, Niederberger V, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J. 2012;26(3):1001–8. Study describes how RV escapes immunity by misdirecting the human antibody response and causes recurrent infections. PubMed Niespodziana K, Napora K, Cabauatan C, Focke-Tejkl M, Keller W, Niederberger V, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J. 2012;26(3):1001–8. Study describes how RV escapes immunity by misdirecting the human antibody response and causes recurrent infections. PubMed
64.
Zurück zum Zitat Katpally U, Fu T-M, Freed DC, Casimiro DR, Smith TJ, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol. 2009;83(14):7040–8.PubMedCentralPubMed Katpally U, Fu T-M, Freed DC, Casimiro DR, Smith TJ, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol. 2009;83(14):7040–8.PubMedCentralPubMed
65.•
Zurück zum Zitat McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res. 2012;95(3):193–201. Study using mouse models to investigate antibody response to RV and reveals strong cross serotype RV-specific IgG responses against the RV capsid protein VP1. PubMed McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res. 2012;95(3):193–201. Study using mouse models to investigate antibody response to RV and reveals strong cross serotype RV-specific IgG responses against the RV capsid protein VP1. PubMed
66.
Zurück zum Zitat Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.PubMed Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.PubMed
67.
Zurück zum Zitat Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther. 2011;28(2):91–109.PubMed Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther. 2011;28(2):91–109.PubMed
68.
Zurück zum Zitat Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692–701.PubMed Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692–701.PubMed
69.••
Zurück zum Zitat Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, et al. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 2011;6(12):e28001. Study describing a human monoclonal antibody capable of neutralizing subtypes responsible of all the reported pandemics, as well as other subtypes with pandemic potential. PubMedCentralPubMed Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, et al. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 2011;6(12):e28001. Study describing a human monoclonal antibody capable of neutralizing subtypes responsible of all the reported pandemics, as well as other subtypes with pandemic potential. PubMedCentralPubMed
70.••
Zurück zum Zitat Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–6. Study describing a neutralizing monoclonal antibody against both group 1 and group 2 influenza A viruses with broad specificity and neutralization potency. PubMed Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–6. Study describing a neutralizing monoclonal antibody against both group 1 and group 2 influenza A viruses with broad specificity and neutralization potency. PubMed
71.
Zurück zum Zitat Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2013;6, CD006362.PubMed Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2013;6, CD006362.PubMed
72.
Zurück zum Zitat Li S et al. Acetaminophen (paracetamol) for the common cold in adults. Cochrane Database Syst Rev. 2013;7, CD008800.PubMed Li S et al. Acetaminophen (paracetamol) for the common cold in adults. Cochrane Database Syst Rev. 2013;7, CD008800.PubMed
73.
Zurück zum Zitat Simons FE. H1-antihistamines in children. Clin Allergy Immunol. 2002;17:437–64.PubMed Simons FE. H1-antihistamines in children. Clin Allergy Immunol. 2002;17:437–64.PubMed
74.
Zurück zum Zitat De Sutter AI, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database Syst Rev. 2012;2:CD004976.PubMed De Sutter AI, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database Syst Rev. 2012;2:CD004976.PubMed
75.
Zurück zum Zitat Meltzer EO, Caballero F, Scadding G. Treatment of congestion in upper respiratory diseases. Int J Gen Med. 2010;3:69–91.PubMedCentralPubMed Meltzer EO, Caballero F, Scadding G. Treatment of congestion in upper respiratory diseases. Int J Gen Med. 2010;3:69–91.PubMedCentralPubMed
76.
Zurück zum Zitat Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Muñoz E, et al. Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012;34(1):98–106.PubMed Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Muñoz E, et al. Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012;34(1):98–106.PubMed
77.
Zurück zum Zitat Albalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev. 2013;6, CD008231.PubMed Albalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev. 2013;6, CD008231.PubMed
78.
Zurück zum Zitat Singh M. Heated, humidified air for the common cold. Cochrane Database Syst Rev. 2013;6, CD001728.PubMed Singh M. Heated, humidified air for the common cold. Cochrane Database Syst Rev. 2013;6, CD001728.PubMed
79.
Zurück zum Zitat Baartmans M et al. Steam inhalation therapy: severe scalds as an adverse side effect. Br J Gen Pract. 2012;62(600):e473–7.PubMedCentralPubMed Baartmans M et al. Steam inhalation therapy: severe scalds as an adverse side effect. Br J Gen Pract. 2012;62(600):e473–7.PubMedCentralPubMed
80.
Zurück zum Zitat Dicpinigaitis PV. Cough: an unmet clinical need. Br J Pharmacol. 2011;163(1):116–24.PubMed Dicpinigaitis PV. Cough: an unmet clinical need. Br J Pharmacol. 2011;163(1):116–24.PubMed
81.
Zurück zum Zitat Sen EF, Verhamme KM, Felisi M, 't Jong GW, Giaquinto C, Picelli G, et al. Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol. 2011;71(6):943–50.PubMed Sen EF, Verhamme KM, Felisi M, 't Jong GW, Giaquinto C, Picelli G, et al. Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol. 2011;71(6):943–50.PubMed
82.
Zurück zum Zitat Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2012;8:CD008116.PubMed Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2012;8:CD008116.PubMed
83.
Zurück zum Zitat Barrett B et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010;153(12):769–77.PubMedCentralPubMed Barrett B et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010;153(12):769–77.PubMedCentralPubMed
84.
Zurück zum Zitat Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2013;6:CD001364.PubMed Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2013;6:CD001364.PubMed
85.
Zurück zum Zitat Mao S, Huang S. Vitamin D supplementation and risk of respiratory tract infections: a meta-analysis of randomized controlled trials. Scand J Infect Dis. 2013;45(9):696–702.PubMed Mao S, Huang S. Vitamin D supplementation and risk of respiratory tract infections: a meta-analysis of randomized controlled trials. Scand J Infect Dis. 2013;45(9):696–702.PubMed
86.
Zurück zum Zitat Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol. 2013;136:321–9.PubMed Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol. 2013;136:321–9.PubMed
87.
Zurück zum Zitat Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD, et al. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(6):e65835.PubMedCentralPubMed Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD, et al. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(6):e65835.PubMedCentralPubMed
88.•
Zurück zum Zitat Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. Clin Infect Dis. 2013;57(3):392–7. This study demonstrate that low serum 25(OH) D levels are associated with increased risk of laboratory-confirmed viral RTI in children in a dose depending way. PubMed Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. Clin Infect Dis. 2013;57(3):392–7. This study demonstrate that low serum 25(OH) D levels are associated with increased risk of laboratory-confirmed viral RTI in children in a dose depending way. PubMed
89.
Zurück zum Zitat Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.PubMed Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.PubMed
90.
Zurück zum Zitat Arroll B. Common cold. Am Fam Physician. 2011;84(12):1390–1.PubMed Arroll B. Common cold. Am Fam Physician. 2011;84(12):1390–1.PubMed
91.
Zurück zum Zitat Maggini S, Beveridge S, Suter M. A combination of high-dose vitamin C plus zinc for the common cold. J Int Med Res. 2012;40(1):28–42.PubMed Maggini S, Beveridge S, Suter M. A combination of high-dose vitamin C plus zinc for the common cold. J Int Med Res. 2012;40(1):28–42.PubMed
92.
Zurück zum Zitat Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;1, CD000980.PubMed Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;1, CD000980.PubMed
93.
Zurück zum Zitat Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;1, CD000530.PubMed Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;1, CD000530.PubMed
94.
Zurück zum Zitat Nahas R, Balla A. Complementary and alternative medicine for prevention and treatment of the common cold. Can Fam Physician. 2011;57(1):31–6.PubMedCentralPubMed Nahas R, Balla A. Complementary and alternative medicine for prevention and treatment of the common cold. Can Fam Physician. 2011;57(1):31–6.PubMedCentralPubMed
95.
Zurück zum Zitat Jawad M et al. Safety and efficacy profile of echinacea purpurea to prevent common cold episodes: a randomized, double-blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2012;2012:841315.PubMedCentralPubMed Jawad M et al. Safety and efficacy profile of echinacea purpurea to prevent common cold episodes: a randomized, double-blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2012;2012:841315.PubMedCentralPubMed
96.
Zurück zum Zitat Kang EJ, Kim SY, Hwang IH, Ji YJ. The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies. Korean J Fam Med. 2013;34(1):2–10.PubMedCentralPubMed Kang EJ, Kim SY, Hwang IH, Ji YJ. The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies. Korean J Fam Med. 2013;34(1):2–10.PubMedCentralPubMed
97.
Zurück zum Zitat Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9, CD006895.PubMed Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9, CD006895.PubMed
98.
Zurück zum Zitat Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682–7.PubMed Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682–7.PubMed
99.
Zurück zum Zitat Shinkai S, Toba M, Saito T, Sato I, Tsubouchi M, Taira K, et al. Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2013;109(10):1856–65.PubMed Shinkai S, Toba M, Saito T, Sato I, Tsubouchi M, Taira K, et al. Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2013;109(10):1856–65.PubMed
100.
Zurück zum Zitat Marotta F et al. Is there a potential application of a fermented nutraceutical in acute respiratory illnesses? An in-vivo placebo-controlled, cross-over clinical study in different age groups of healthy subjects. J Biol Regul Homeost Agents. 2012;26(2):285–94.PubMed Marotta F et al. Is there a potential application of a fermented nutraceutical in acute respiratory illnesses? An in-vivo placebo-controlled, cross-over clinical study in different age groups of healthy subjects. J Biol Regul Homeost Agents. 2012;26(2):285–94.PubMed
101.•
Zurück zum Zitat Ganesan S, Faris AN, Wang Q, Nanua S, Hershenson MB, et al. Quercetin inhibits rhinovirus replication in vitro and in vivo. Antiviral Res. 2012;94(3):258–71. Study demonstrating in vivo and in vitro that quercetin decreases RV infection at multiple steps in the viral life cycle. PubMedCentralPubMed Ganesan S, Faris AN, Wang Q, Nanua S, Hershenson MB, et al. Quercetin inhibits rhinovirus replication in vitro and in vivo. Antiviral Res. 2012;94(3):258–71. Study demonstrating in vivo and in vitro that quercetin decreases RV infection at multiple steps in the viral life cycle. PubMedCentralPubMed
102.
Zurück zum Zitat Song JH, Park KS, Kwon DH, Choi HJ. Anti-human rhinovirus 2 activity and mode of action of quercetin-7-glucoside from Lagerstroemia speciosa. J Med Food. 2013;16(4):274–9.PubMed Song JH, Park KS, Kwon DH, Choi HJ. Anti-human rhinovirus 2 activity and mode of action of quercetin-7-glucoside from Lagerstroemia speciosa. J Med Food. 2013;16(4):274–9.PubMed
103.
Zurück zum Zitat Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol Res. 2010;62(3):237–42.PubMed Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol Res. 2010;62(3):237–42.PubMed
104.•
Zurück zum Zitat Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of upper respiratory infections. Curr Med Res Opin. 2013;29(3):251–8. A clinical trial demonstrating that larch arabinogalactan increase the body’s potential to defend against common cold infection. PubMed Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of upper respiratory infections. Curr Med Res Opin. 2013;29(3):251–8. A clinical trial demonstrating that larch arabinogalactan increase the body’s potential to defend against common cold infection. PubMed
105.
Zurück zum Zitat Leibbrandt A, Meier C, König-Schuster M, Weinmüllner R, Kalthoff D, Pflugfelder B, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010;5(12):e14320.PubMedCentralPubMed Leibbrandt A, Meier C, König-Schuster M, Weinmüllner R, Kalthoff D, Pflugfelder B, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010;5(12):e14320.PubMedCentralPubMed
106.
Zurück zum Zitat Grassauer A, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008;5:107.PubMedCentralPubMed Grassauer A, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008;5:107.PubMedCentralPubMed
107.
Zurück zum Zitat Eccles R, Meier C, Prieschl-Grassauer E. Efficacy and safety of an antiviral iota-carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010;11:108.PubMedCentralPubMed Eccles R, Meier C, Prieschl-Grassauer E. Efficacy and safety of an antiviral iota-carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010;11:108.PubMedCentralPubMed
108.
Zurück zum Zitat Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med. 2012;12:147.PubMedCentralPubMed Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med. 2012;12:147.PubMedCentralPubMed
109.
Zurück zum Zitat Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013;52(8):1913–8.PubMedCentralPubMed Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013;52(8):1913–8.PubMedCentralPubMed
110.
Zurück zum Zitat Graubaum H-J, Busch R, Stier H, Gruenwald J. A doubleblind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nut Sci. 2012;3:738–46. Graubaum H-J, Busch R, Stier H, Gruenwald J. A doubleblind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nut Sci. 2012;3:738–46.
111.
Zurück zum Zitat Yates PJ et al. Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob Agents Chemother. 2013;57(4):1677–84.PubMedCentralPubMed Yates PJ et al. Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob Agents Chemother. 2013;57(4):1677–84.PubMedCentralPubMed
112.
Zurück zum Zitat Michiels B et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.PubMedCentralPubMed Michiels B et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.PubMedCentralPubMed
113.
Zurück zum Zitat Wang K et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;4:CD002744.PubMed Wang K et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;4:CD002744.PubMed
114.
Zurück zum Zitat Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98.PubMedCentralPubMed Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98.PubMedCentralPubMed
115.•
Zurück zum Zitat Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011;38(2):401–8. This study describes a new antiviral agent that reduces RSV replication and inhibits lung inflammation in mice. PubMed Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011;38(2):401–8. This study describes a new antiviral agent that reduces RSV replication and inhibits lung inflammation in mice. PubMed
116.
Zurück zum Zitat Sun Z et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Virus. 2013;5(1):211–25. Sun Z et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Virus. 2013;5(1):211–25.
117.
Zurück zum Zitat Maugeri C et al. New anti-viral drugs for the treatment of the common cold. Bioorg Med Chem. 2008;16(6):3091–107.PubMed Maugeri C et al. New anti-viral drugs for the treatment of the common cold. Bioorg Med Chem. 2008;16(6):3091–107.PubMed
118.
Zurück zum Zitat Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71(2–3):391–6.PubMed Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71(2–3):391–6.PubMed
119.•
Zurück zum Zitat Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2011;31(1):42–92. This is an extensive review of existing knowledge about mechanisms of anti-RV agents from synthetic and natural origin, and future potentials. PubMed Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2011;31(1):42–92. This is an extensive review of existing knowledge about mechanisms of anti-RV agents from synthetic and natural origin, and future potentials. PubMed
120.
Zurück zum Zitat Gwaltney Jr JM et al. Combined antiviral-antimediator treatment for the common cold. J Infect Dis. 2002;186(2):147–54.PubMed Gwaltney Jr JM et al. Combined antiviral-antimediator treatment for the common cold. J Infect Dis. 2002;186(2):147–54.PubMed
121.
Zurück zum Zitat Gao L et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28(28):4445–51.PubMed Gao L et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28(28):4445–51.PubMed
122.••
Zurück zum Zitat Campbell-Harding G, Sawkins H, Bedke N, Holgate ST, Davies DE, Andrews AL, et al. The innate antiviral response upregulates IL-13 receptor alpha2 in bronchial fibroblasts. J Allergy Clin Immunol. 2013;131(3):849–55. This study enlightens the role of IFN-beta and IL-13 in innate antiviral immune response. PubMed Campbell-Harding G, Sawkins H, Bedke N, Holgate ST, Davies DE, Andrews AL, et al. The innate antiviral response upregulates IL-13 receptor alpha2 in bronchial fibroblasts. J Allergy Clin Immunol. 2013;131(3):849–55. This study enlightens the role of IFN-beta and IL-13 in innate antiviral immune response. PubMed
123.
Zurück zum Zitat Yamaya M et al. Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Antimicrob Agents Chemother. 2012;56(8):4052–61.PubMedCentralPubMed Yamaya M et al. Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Antimicrob Agents Chemother. 2012;56(8):4052–61.PubMedCentralPubMed
124.
Zurück zum Zitat Koutsoubari I et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatr Allergy Immunol. 2012;23(4):385–90.PubMed Koutsoubari I et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatr Allergy Immunol. 2012;23(4):385–90.PubMed
125.
126.
Zurück zum Zitat Jurgeit A et al. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012;8(10):e1002976.PubMedCentralPubMed Jurgeit A et al. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012;8(10):e1002976.PubMedCentralPubMed
127.
Zurück zum Zitat Yoshihara S et al. Inhibition of common cold-induced aggravation of childhood asthma by leukotriene receptor antagonists. Allergol Int. 2012;61(3):405–10.PubMed Yoshihara S et al. Inhibition of common cold-induced aggravation of childhood asthma by leukotriene receptor antagonists. Allergol Int. 2012;61(3):405–10.PubMed
128.
Zurück zum Zitat Kozer E et al. RCT of montelukast as prophylaxis for upper respiratory tract infections in children. Pediatrics. 2012;129(2):e285–90.PubMed Kozer E et al. RCT of montelukast as prophylaxis for upper respiratory tract infections in children. Pediatrics. 2012;129(2):e285–90.PubMed
129.
Zurück zum Zitat Kloepfer KM. Effects of montelukast on patients with asthma after experimental inoculation with human rhinovirus 16. Ann Allergy Asthma Immunol. 2011;106(3):252–7.PubMedCentralPubMed Kloepfer KM. Effects of montelukast on patients with asthma after experimental inoculation with human rhinovirus 16. Ann Allergy Asthma Immunol. 2011;106(3):252–7.PubMedCentralPubMed
130.
Zurück zum Zitat Yamaya M et al. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur Respir J. 2012;40(1):122–32.PubMed Yamaya M et al. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur Respir J. 2012;40(1):122–32.PubMed
131.
Zurück zum Zitat Gern JE et al. Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis. 2007;195(8):1137–43.PubMed Gern JE et al. Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis. 2007;195(8):1137–43.PubMed
132.
Zurück zum Zitat Van Blerkom LM. Role of viruses in human evolution. Am J Phys Anthropol. 2003;37:14–46.PubMed Van Blerkom LM. Role of viruses in human evolution. Am J Phys Anthropol. 2003;37:14–46.PubMed
Metadaten
Titel
The Common Cold: Potential for Future Prevention or Cure
verfasst von
Maria Passioti
Paraskevi Maggina
Spyridon Megremis
Nikolaos G. Papadopoulos
Publikationsdatum
01.02.2014
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 2/2014
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-013-0413-5

Weitere Artikel der Ausgabe 2/2014

Current Allergy and Asthma Reports 2/2014 Zur Ausgabe

RHINITIS (JJ OPPENHEIMER AND J CORREN, SECTION EDITORS)

Preventing Progression of Allergic Rhinitis to Asthma

RHINITIS (JJ OPPENHEIMER AND J CORREN, SECTION EDITORS)

Indications for Surgery in Refractory Rhinitis

RHINOSINUSITIS (J MULLOL, SECTION EDITOR)

MicroRNA in Chronic Rhinosinusitis and Allergic Rhinitis

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.